Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

State Pseudoephedrine Proposals Go Above, Beyond Combat Meth Act

This article was originally published in The Tan Sheet

Executive Summary

The National Association of Chain Drug Stores has "concerns" with state bills proposing the establishment of real-time electronic repositories to monitor and limit pseudoephedrine sales, according to the trade group

You may also be interested in...



Research Refutes Rx-Only Pseudoephedrine Requirements

Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.

Research Refutes Rx-Only Pseudoephedrine Requirements

Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.

Wyden's Rx Pseudoephedrine Bill On Doorstep As States Continue Meth Fight

Sen. Ron Wyden says he will introduce legislation to make pseudoephedrine-containing drugs available by prescription only - a measure that could gain traction among states waging their own battles against methamphetamine

Related Content

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel